MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why LITS Stock dropped -4.88% Today — RQD Quant Desk Flash
$1.17 -4.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.16
Lite Strategy Inc. (LITS) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $35.6M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.16 (-1.07%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LITS)Realized 20D OHLCV Swing Band: ±12.1%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY LITS SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (31% of score)
Altman Z-Score 11.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)
FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 44 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.27-9.4% Next Q
50
Q2 (-2Q)Grade D$1.15+0.9% Next Q
47
Q3 (-1Q)Grade D$1.16+0.9% Next Q
45
CurrentGrade D-$1.17-7% Hist 90D α
42
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LITS Turnaround Squeeze
While LITS currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.17) and Max Pain ($1.23) forces dealer call-delta covering toward $2.37.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LITS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LITS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LITS Stock dropped -4.88% Today — RQD Quant Desk Flash
Lite Strategy Inc. (LITS) dropped -4.88% to $1.17, trading at 31% of its 52-week range ($0.69 – $2.26). Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 31% of its 52-week range ($0.69 – $2.26) with RSI-14 at 44 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.1% around $1.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LITS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LITS)
- ✓Walkthrough of LITS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LITS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.74%▲ ASCENDING CHANNEL
2026-10-30O $1.17H $1.17L $1.10C $1.17VOL 270.5K
RES: $1.75SUP: $1.03SMA50: $1.17SMA200: $1.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LITS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LITS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LITS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LITS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LITS)
Health Care Rank #589 of 1016
⚔️ EDSA vs LITS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LITS vs. EDSA, NNVC, NSRX, ACET)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Lite Strategy Inc. (LITS) ranks #589 by composite RQD confidence (42/100, grade D-) and #788 by equity capitalization ($35.6M). Within this direct 5-issuer industry benchmark cohort, LITS leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LITS
ACTIVE
Lite Strategy Inc. | D- | 42/100 | — | — | -18.9% | -4.88% | $35.6M | Benchmark Subject |
| EDSA Edesa Biotech Inc. | D- | 42/100 | — | — | -35.0% | +5.47% | $36.5M | /edsa-vs-lits → |
| NNVC NanoViricides Inc. | E | 33/100 | — | — | -35.0% | -1.38% | $36.5M | /nnvc-vs-lits → |
| NSRX Nasus Pharma Ltd. | D- | 36/100 | — | — | -35.0% | -4.49% | $37.4M | /nsrx-vs-lits → |
| ACET Adicet Bio Inc. | D- | 36/100 | — | — | -35.0% | -6.04% | $33.5M | /acet-vs-lits → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001262104In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lite Strategy Inc. (LITS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $65.3M , and -100.0% cumulative change since FY2023) , GAAP net income of -$15.9M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (+58.7% YoY). On the balance sheet, LITS closed FY2025 with $82.9M in total assets against $0 in total debt (Altman Z-Score: 11.68, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$15.9M | -$20.8M | -$20.8M | $82.9M | — |
| FY2024 (FY) | 2024-06-30 | $65.3M | $18.0M | -$50.5M | -$50.5M | $24.4M | — |
| FY2023 (FY) | 2023-06-30 | $48.8M | -$32.0M | -$52.5M | -$52.5M | — | — |
3. LITS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Lite Strategy Inc. (NASDAQ: LITS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.17 (-4.88% 1D, market cap $35.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LITS ranks #589 in composite RQD confidence.
How does LITS compare to EDSA and NNVC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LITS carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, EDSA (Edesa Biotech Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M) and NNVC (NanoViricides Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M). Among the 5-stock peer group, LITS leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LITS?
Per LITS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001262104), Lite Strategy Inc. generated $0 in revenue (-100.0% YoY), -$15.9M in net income, and -$20.8M in free cash flow against $82.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LITS trading relative to its 50-day, 200-day, and 52-week technical levels?
LITS last traded at $1.17 (-4.88% on volume of 341,057 shares), positioning the stock 0.00% above its 50-day simple moving average ($1.17) and +7.34% above its 200-day simple moving average ($1.09). Across its 52-week range of $0.69 to $2.26, LITS sits at the 30.6% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($1.03 to $1.31).
LITS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LITS stock moving today?
Why LITS Stock dropped -4.88% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.